Provided by Tiger Trade Technology Pte. Ltd.

Immutep Limited

0.3861
-0.0050-1.28%
Post-market: 0.38700.0009+0.23%18:01 EDT
Volume:113.89K
Turnover:43.94K
Market Cap:56.83M
PE:-1.01
High:0.4000
Open:0.4000
Low:0.3823
Close:0.3911
52wk High:3.53
52wk Low:0.2928
Shares:147.19M
Float Shares:143.00M
Volume Ratio:1.51
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3822
EPS(LYR):-0.2767
ROE:-61.85%
ROA:-32.10%
PB:0.80
PE(LYR):-1.40

Loading ...

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

GlobeNewswire
·
Jul 24

Immutep Granted New US Patent for Cancer Treatment Methods

MT Newswires Live
·
Jul 14

Immutep granted new patent for eftilagimod alfa combination

TIPRANKS
·
Jul 14

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

GlobeNewswire
·
Jul 14

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

GlobeNewswire
·
Jul 13

Immutep Shares Rise After Maxim Group Upgrade

MT Newswires Live
·
Jun 18

Immutep Raised to Buy From Hold by Maxim Group

Dow Jones
·
Jun 17

Maxim Group Upgrades Immutep to Buy From Hold, $1.50 Price Target

MT Newswires Live
·
Jun 17

Immutep Ltd : Maxim Group Raises to Buy From Hold

THOMSON REUTERS
·
Jun 17

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

GlobeNewswire
·
Jun 04

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

GlobeNewswire
·
May 28

Immutep Hit With Securities Suit After TACTI-004 Trial Halt and 83% Stock Drop

TIPRANKS
·
May 22

Immutep Faces Securities Lawsuit After 83% Stock Collapse Following Phase III Trial Discontinuation

TIPRANKS
·
May 16

Largest borrow rate increases among liquid names

TIPRANKS
·
May 09

Immutep Receives Nasdaq Notice of Bid Price Deficiency

GlobeNewswire
·
Apr 30

Immutep Quarterly Activities Report Q3 FY26

GlobeNewswire
·
Apr 30

Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

GlobeNewswire
·
Apr 22

NASD Most Active Issues

Dow Jones
·
Apr 16

Immutep Gets FDA Boost For Lead Cancer Drug, Stock Doubles

Benzinga_recent_news
·
Apr 16

Unusually active option classes on open April 15th

TIPRANKS
·
Apr 15